nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—PTGS1—esophageal cancer	0.342	0.636	CbGaD
Thalidomide—PTGS2—esophageal cancer	0.196	0.364	CbGaD
Thalidomide—PTGS2—Cisplatin—esophageal cancer	0.0361	0.496	CbGbCtD
Thalidomide—CYP2C9—Capecitabine—esophageal cancer	0.0244	0.335	CbGbCtD
Thalidomide—CYP2C9—Cisplatin—esophageal cancer	0.0123	0.169	CbGbCtD
Thalidomide—FGFR2—exocrine gland—esophageal cancer	0.00476	0.0951	CbGeAlD
Thalidomide—FGFR2—neck—esophageal cancer	0.00304	0.0608	CbGeAlD
Thalidomide—NFKB1—bronchus—esophageal cancer	0.00272	0.0542	CbGeAlD
Thalidomide—NFKB1—trachea—esophageal cancer	0.00244	0.0487	CbGeAlD
Thalidomide—CRBN—bronchus—esophageal cancer	0.00228	0.0454	CbGeAlD
Thalidomide—TNF—lymph node—esophageal cancer	0.0021	0.042	CbGeAlD
Thalidomide—NFKB1—digestive system—esophageal cancer	0.0021	0.0419	CbGeAlD
Thalidomide—FGFR2—epithelium—esophageal cancer	0.00207	0.0413	CbGeAlD
Thalidomide—CRBN—trachea—esophageal cancer	0.00204	0.0408	CbGeAlD
Thalidomide—FGFR2—smooth muscle tissue—esophageal cancer	0.002	0.0398	CbGeAlD
Thalidomide—CRBN—digestive system—esophageal cancer	0.00176	0.0351	CbGeAlD
Thalidomide—NFKB1—lung—esophageal cancer	0.00175	0.035	CbGeAlD
Thalidomide—FGFR2—digestive system—esophageal cancer	0.00158	0.0315	CbGeAlD
Thalidomide—CRBN—lung—esophageal cancer	0.00147	0.0293	CbGeAlD
Thalidomide—FGFR2—lung—esophageal cancer	0.00132	0.0263	CbGeAlD
Thalidomide—NFKB1—lymph node—esophageal cancer	0.0012	0.0239	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—esophageal cancer	0.0011	0.22	CrCbGaD
Thalidomide—Menadione—CYP2A6—esophageal cancer	0.00107	0.214	CrCbGaD
Thalidomide—Pomalidomide—PTGS2—esophageal cancer	0.00102	0.205	CrCbGaD
Thalidomide—CRBN—lymph node—esophageal cancer	0.001	0.0201	CbGeAlD
Thalidomide—Lenalidomide—ABCB1—esophageal cancer	0.000935	0.187	CrCbGaD
Thalidomide—Pomalidomide—ABCB1—esophageal cancer	0.000869	0.174	CrCbGaD
Thalidomide—CYP1A1—epithelium—esophageal cancer	0.000749	0.015	CbGeAlD
Thalidomide—CYP1A1—bronchus—esophageal cancer	0.000738	0.0147	CbGeAlD
Thalidomide—CYP2C19—digestive system—esophageal cancer	0.000708	0.0141	CbGeAlD
Thalidomide—CYP1A1—trachea—esophageal cancer	0.000663	0.0132	CbGeAlD
Thalidomide—PTGS1—epithelium—esophageal cancer	0.000658	0.0131	CbGeAlD
Thalidomide—PTGS1—smooth muscle tissue—esophageal cancer	0.000634	0.0127	CbGeAlD
Thalidomide—PTGS2—epithelium—esophageal cancer	0.000629	0.0126	CbGeAlD
Thalidomide—PTGS2—bronchus—esophageal cancer	0.00062	0.0124	CbGeAlD
Thalidomide—PTGS2—smooth muscle tissue—esophageal cancer	0.000606	0.0121	CbGeAlD
Thalidomide—PTGS1—trachea—esophageal cancer	0.000582	0.0116	CbGeAlD
Thalidomide—CYP1A2—digestive system—esophageal cancer	0.000578	0.0115	CbGeAlD
Thalidomide—CYP1A1—digestive system—esophageal cancer	0.00057	0.0114	CbGeAlD
Thalidomide—CYP3A5—digestive system—esophageal cancer	0.000557	0.0111	CbGeAlD
Thalidomide—PTGS2—trachea—esophageal cancer	0.000556	0.0111	CbGeAlD
Thalidomide—CYP2C9—digestive system—esophageal cancer	0.000549	0.011	CbGeAlD
Thalidomide—CYP2E1—digestive system—esophageal cancer	0.00052	0.0104	CbGeAlD
Thalidomide—PTGS1—digestive system—esophageal cancer	0.000501	0.01	CbGeAlD
Thalidomide—CYP1A2—lung—esophageal cancer	0.000483	0.00964	CbGeAlD
Thalidomide—PTGS2—digestive system—esophageal cancer	0.000479	0.00956	CbGeAlD
Thalidomide—CYP1A1—lung—esophageal cancer	0.000476	0.00951	CbGeAlD
Thalidomide—CYP3A5—lung—esophageal cancer	0.000466	0.0093	CbGeAlD
Thalidomide—CYP2E1—lung—esophageal cancer	0.000434	0.00867	CbGeAlD
Thalidomide—PTGS1—lung—esophageal cancer	0.000418	0.00835	CbGeAlD
Thalidomide—PTGS2—lung—esophageal cancer	0.0004	0.00798	CbGeAlD
Thalidomide—CYP1A1—lymph node—esophageal cancer	0.000326	0.0065	CbGeAlD
Thalidomide—PTGS1—lymph node—esophageal cancer	0.000286	0.00571	CbGeAlD
Thalidomide—PTGS2—lymph node—esophageal cancer	0.000273	0.00546	CbGeAlD
Thalidomide—Tinnitus—Cisplatin—esophageal cancer	0.000252	0.00167	CcSEcCtD
Thalidomide—Lymphadenopathy—Methotrexate—esophageal cancer	0.000252	0.00166	CcSEcCtD
Thalidomide—Cardiac disorder—Cisplatin—esophageal cancer	0.000251	0.00166	CcSEcCtD
Thalidomide—Abdominal distension—Capecitabine—esophageal cancer	0.000251	0.00166	CcSEcCtD
Thalidomide—Influenza—Capecitabine—esophageal cancer	0.000249	0.00165	CcSEcCtD
Thalidomide—Dysphagia—Capecitabine—esophageal cancer	0.000249	0.00165	CcSEcCtD
Thalidomide—Thrombophlebitis—Methotrexate—esophageal cancer	0.000248	0.00164	CcSEcCtD
Thalidomide—Diabetes mellitus—Methotrexate—esophageal cancer	0.000247	0.00163	CcSEcCtD
Thalidomide—Bronchospasm—Capecitabine—esophageal cancer	0.000245	0.00162	CcSEcCtD
Thalidomide—Photosensitivity—Methotrexate—esophageal cancer	0.000244	0.00162	CcSEcCtD
Thalidomide—Immune system disorder—Cisplatin—esophageal cancer	0.000244	0.00162	CcSEcCtD
Thalidomide—Mediastinal disorder—Cisplatin—esophageal cancer	0.000244	0.00161	CcSEcCtD
Thalidomide—Angina pectoris—Capecitabine—esophageal cancer	0.000243	0.00161	CcSEcCtD
Thalidomide—Arrhythmia—Cisplatin—esophageal cancer	0.000242	0.0016	CcSEcCtD
Thalidomide—Bronchitis—Capecitabine—esophageal cancer	0.00024	0.00159	CcSEcCtD
Thalidomide—Alopecia—Cisplatin—esophageal cancer	0.000239	0.00158	CcSEcCtD
Thalidomide—Pancytopenia—Capecitabine—esophageal cancer	0.000237	0.00157	CcSEcCtD
Thalidomide—Malnutrition—Cisplatin—esophageal cancer	0.000236	0.00156	CcSEcCtD
Thalidomide—Neutropenia—Capecitabine—esophageal cancer	0.000233	0.00154	CcSEcCtD
Thalidomide—Renal failure acute—Methotrexate—esophageal cancer	0.000233	0.00154	CcSEcCtD
Thalidomide—Flatulence—Cisplatin—esophageal cancer	0.000232	0.00154	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000232	0.00153	CcSEcCtD
Thalidomide—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000227	0.0015	CcSEcCtD
Thalidomide—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000227	0.0015	CcSEcCtD
Thalidomide—Weight increased—Capecitabine—esophageal cancer	0.000227	0.0015	CcSEcCtD
Thalidomide—Visual disturbance—Methotrexate—esophageal cancer	0.000227	0.0015	CcSEcCtD
Thalidomide—Muscle spasms—Cisplatin—esophageal cancer	0.000226	0.0015	CcSEcCtD
Thalidomide—Weight decreased—Capecitabine—esophageal cancer	0.000225	0.00149	CcSEcCtD
Thalidomide—Hyperglycaemia—Capecitabine—esophageal cancer	0.000225	0.00149	CcSEcCtD
Thalidomide—Pneumonia—Capecitabine—esophageal cancer	0.000224	0.00148	CcSEcCtD
Thalidomide—Infestation NOS—Capecitabine—esophageal cancer	0.000222	0.00147	CcSEcCtD
Thalidomide—Infestation—Capecitabine—esophageal cancer	0.000222	0.00147	CcSEcCtD
Thalidomide—Vision blurred—Cisplatin—esophageal cancer	0.000222	0.00147	CcSEcCtD
Thalidomide—Depression—Capecitabine—esophageal cancer	0.000222	0.00147	CcSEcCtD
Thalidomide—Tremor—Cisplatin—esophageal cancer	0.000221	0.00146	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00022	0.00146	CcSEcCtD
Thalidomide—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000219	0.00145	CcSEcCtD
Thalidomide—Lethargy—Methotrexate—esophageal cancer	0.000219	0.00145	CcSEcCtD
Thalidomide—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000219	0.00145	CcSEcCtD
Thalidomide—Ill-defined disorder—Cisplatin—esophageal cancer	0.000219	0.00145	CcSEcCtD
Thalidomide—Renal failure—Capecitabine—esophageal cancer	0.000218	0.00145	CcSEcCtD
Thalidomide—Myocardial infarction—Capecitabine—esophageal cancer	0.000218	0.00144	CcSEcCtD
Thalidomide—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000218	0.00144	CcSEcCtD
Thalidomide—Anaemia—Cisplatin—esophageal cancer	0.000218	0.00144	CcSEcCtD
Thalidomide—Stomatitis—Capecitabine—esophageal cancer	0.000217	0.00143	CcSEcCtD
Thalidomide—Conjunctivitis—Capecitabine—esophageal cancer	0.000216	0.00143	CcSEcCtD
Thalidomide—Osteoarthritis—Methotrexate—esophageal cancer	0.000215	0.00142	CcSEcCtD
Thalidomide—Malaise—Cisplatin—esophageal cancer	0.000212	0.00141	CcSEcCtD
Thalidomide—Haematuria—Capecitabine—esophageal cancer	0.000212	0.0014	CcSEcCtD
Thalidomide—Leukopenia—Cisplatin—esophageal cancer	0.000211	0.0014	CcSEcCtD
Thalidomide—Epistaxis—Capecitabine—esophageal cancer	0.00021	0.00139	CcSEcCtD
Thalidomide—Agranulocytosis—Capecitabine—esophageal cancer	0.000207	0.00137	CcSEcCtD
Thalidomide—Convulsion—Cisplatin—esophageal cancer	0.000204	0.00135	CcSEcCtD
Thalidomide—Mood swings—Methotrexate—esophageal cancer	0.000203	0.00135	CcSEcCtD
Thalidomide—Bradycardia—Capecitabine—esophageal cancer	0.000203	0.00134	CcSEcCtD
Thalidomide—Ataxia—Methotrexate—esophageal cancer	0.000202	0.00134	CcSEcCtD
Thalidomide—Myalgia—Cisplatin—esophageal cancer	0.000201	0.00133	CcSEcCtD
Thalidomide—Rhinitis—Capecitabine—esophageal cancer	0.0002	0.00132	CcSEcCtD
Thalidomide—Anxiety—Cisplatin—esophageal cancer	0.0002	0.00132	CcSEcCtD
Thalidomide—Hepatitis—Capecitabine—esophageal cancer	0.000199	0.00132	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000199	0.00132	CcSEcCtD
Thalidomide—Hypoaesthesia—Capecitabine—esophageal cancer	0.000198	0.00131	CcSEcCtD
Thalidomide—Liver function test abnormal—Methotrexate—esophageal cancer	0.000198	0.00131	CcSEcCtD
Thalidomide—Discomfort—Cisplatin—esophageal cancer	0.000198	0.00131	CcSEcCtD
Thalidomide—Pharyngitis—Capecitabine—esophageal cancer	0.000198	0.00131	CcSEcCtD
Thalidomide—Urinary tract disorder—Capecitabine—esophageal cancer	0.000197	0.0013	CcSEcCtD
Thalidomide—Oedema peripheral—Capecitabine—esophageal cancer	0.000197	0.0013	CcSEcCtD
Thalidomide—Urethral disorder—Capecitabine—esophageal cancer	0.000196	0.00129	CcSEcCtD
Thalidomide—Breast disorder—Methotrexate—esophageal cancer	0.000194	0.00128	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000193	0.00128	CcSEcCtD
Thalidomide—Oedema—Cisplatin—esophageal cancer	0.000192	0.00127	CcSEcCtD
Thalidomide—Visual impairment—Capecitabine—esophageal cancer	0.000192	0.00127	CcSEcCtD
Thalidomide—Infection—Cisplatin—esophageal cancer	0.000191	0.00126	CcSEcCtD
Thalidomide—Erythema multiforme—Capecitabine—esophageal cancer	0.000189	0.00125	CcSEcCtD
Thalidomide—Nervous system disorder—Cisplatin—esophageal cancer	0.000189	0.00125	CcSEcCtD
Thalidomide—Thrombocytopenia—Cisplatin—esophageal cancer	0.000188	0.00125	CcSEcCtD
Thalidomide—Tachycardia—Cisplatin—esophageal cancer	0.000188	0.00124	CcSEcCtD
Thalidomide—Skin disorder—Cisplatin—esophageal cancer	0.000187	0.00124	CcSEcCtD
Thalidomide—Eye disorder—Capecitabine—esophageal cancer	0.000186	0.00123	CcSEcCtD
Thalidomide—Tinnitus—Capecitabine—esophageal cancer	0.000186	0.00123	CcSEcCtD
Thalidomide—Hyperhidrosis—Cisplatin—esophageal cancer	0.000186	0.00123	CcSEcCtD
Thalidomide—Cardiac disorder—Capecitabine—esophageal cancer	0.000185	0.00122	CcSEcCtD
Thalidomide—Eosinophilia—Methotrexate—esophageal cancer	0.000184	0.00122	CcSEcCtD
Thalidomide—Anorexia—Cisplatin—esophageal cancer	0.000183	0.00121	CcSEcCtD
Thalidomide—Pancreatitis—Methotrexate—esophageal cancer	0.000182	0.0012	CcSEcCtD
Thalidomide—Angiopathy—Capecitabine—esophageal cancer	0.000181	0.0012	CcSEcCtD
Thalidomide—Immune system disorder—Capecitabine—esophageal cancer	0.00018	0.00119	CcSEcCtD
Thalidomide—Mediastinal disorder—Capecitabine—esophageal cancer	0.00018	0.00119	CcSEcCtD
Thalidomide—Hypotension—Cisplatin—esophageal cancer	0.00018	0.00119	CcSEcCtD
Thalidomide—Chills—Capecitabine—esophageal cancer	0.000179	0.00118	CcSEcCtD
Thalidomide—Arrhythmia—Capecitabine—esophageal cancer	0.000178	0.00118	CcSEcCtD
Thalidomide—Alopecia—Capecitabine—esophageal cancer	0.000176	0.00117	CcSEcCtD
Thalidomide—Pancytopenia—Methotrexate—esophageal cancer	0.000176	0.00117	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000175	0.00116	CcSEcCtD
Thalidomide—Mental disorder—Capecitabine—esophageal cancer	0.000175	0.00116	CcSEcCtD
Thalidomide—Malnutrition—Capecitabine—esophageal cancer	0.000174	0.00115	CcSEcCtD
Thalidomide—Neutropenia—Methotrexate—esophageal cancer	0.000173	0.00115	CcSEcCtD
Thalidomide—Paraesthesia—Cisplatin—esophageal cancer	0.000173	0.00114	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000172	0.00114	CcSEcCtD
Thalidomide—Dyspnoea—Cisplatin—esophageal cancer	0.000171	0.00113	CcSEcCtD
Thalidomide—Flatulence—Capecitabine—esophageal cancer	0.000171	0.00113	CcSEcCtD
Thalidomide—Erectile dysfunction—Methotrexate—esophageal cancer	0.000171	0.00113	CcSEcCtD
Thalidomide—Dysgeusia—Capecitabine—esophageal cancer	0.00017	0.00113	CcSEcCtD
Thalidomide—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000169	0.00112	CcSEcCtD
Thalidomide—Back pain—Capecitabine—esophageal cancer	0.000168	0.00111	CcSEcCtD
Thalidomide—Decreased appetite—Cisplatin—esophageal cancer	0.000167	0.00111	CcSEcCtD
Thalidomide—Muscle spasms—Capecitabine—esophageal cancer	0.000167	0.0011	CcSEcCtD
Thalidomide—Pneumonia—Methotrexate—esophageal cancer	0.000166	0.0011	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000166	0.0011	CcSEcCtD
Thalidomide—Drowsiness—Methotrexate—esophageal cancer	0.000165	0.00109	CcSEcCtD
Thalidomide—Infestation NOS—Methotrexate—esophageal cancer	0.000165	0.00109	CcSEcCtD
Thalidomide—Infestation—Methotrexate—esophageal cancer	0.000165	0.00109	CcSEcCtD
Thalidomide—Depression—Methotrexate—esophageal cancer	0.000165	0.00109	CcSEcCtD
Thalidomide—Pain—Cisplatin—esophageal cancer	0.000164	0.00109	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000164	0.00108	CcSEcCtD
Thalidomide—Vision blurred—Capecitabine—esophageal cancer	0.000164	0.00108	CcSEcCtD
Thalidomide—Tremor—Capecitabine—esophageal cancer	0.000163	0.00108	CcSEcCtD
Thalidomide—Renal failure—Methotrexate—esophageal cancer	0.000163	0.00108	CcSEcCtD
Thalidomide—Stomatitis—Methotrexate—esophageal cancer	0.000161	0.00107	CcSEcCtD
Thalidomide—Ill-defined disorder—Capecitabine—esophageal cancer	0.000161	0.00107	CcSEcCtD
Thalidomide—Conjunctivitis—Methotrexate—esophageal cancer	0.000161	0.00106	CcSEcCtD
Thalidomide—Anaemia—Capecitabine—esophageal cancer	0.000161	0.00106	CcSEcCtD
Thalidomide—Sweating—Methotrexate—esophageal cancer	0.000159	0.00105	CcSEcCtD
Thalidomide—Feeling abnormal—Cisplatin—esophageal cancer	0.000158	0.00105	CcSEcCtD
Thalidomide—Haematuria—Methotrexate—esophageal cancer	0.000158	0.00104	CcSEcCtD
Thalidomide—Malaise—Capecitabine—esophageal cancer	0.000157	0.00104	CcSEcCtD
Thalidomide—Epistaxis—Methotrexate—esophageal cancer	0.000156	0.00103	CcSEcCtD
Thalidomide—Vertigo—Capecitabine—esophageal cancer	0.000156	0.00103	CcSEcCtD
Thalidomide—Syncope—Capecitabine—esophageal cancer	0.000156	0.00103	CcSEcCtD
Thalidomide—Leukopenia—Capecitabine—esophageal cancer	0.000155	0.00103	CcSEcCtD
Thalidomide—Agranulocytosis—Methotrexate—esophageal cancer	0.000154	0.00102	CcSEcCtD
Thalidomide—Palpitations—Capecitabine—esophageal cancer	0.000153	0.00102	CcSEcCtD
Thalidomide—Loss of consciousness—Capecitabine—esophageal cancer	0.000153	0.00101	CcSEcCtD
Thalidomide—Body temperature increased—Cisplatin—esophageal cancer	0.000152	0.00101	CcSEcCtD
Thalidomide—Cough—Capecitabine—esophageal cancer	0.000152	0.001	CcSEcCtD
Thalidomide—Hypertension—Capecitabine—esophageal cancer	0.00015	0.000992	CcSEcCtD
Thalidomide—Hepatitis—Methotrexate—esophageal cancer	0.000149	0.000982	CcSEcCtD
Thalidomide—Myalgia—Capecitabine—esophageal cancer	0.000148	0.000978	CcSEcCtD
Thalidomide—Chest pain—Capecitabine—esophageal cancer	0.000148	0.000978	CcSEcCtD
Thalidomide—Arthralgia—Capecitabine—esophageal cancer	0.000148	0.000978	CcSEcCtD
Thalidomide—Pharyngitis—Methotrexate—esophageal cancer	0.000147	0.000975	CcSEcCtD
Thalidomide—Anxiety—Capecitabine—esophageal cancer	0.000147	0.000975	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000147	0.000971	CcSEcCtD
Thalidomide—Urinary tract disorder—Methotrexate—esophageal cancer	0.000147	0.00097	CcSEcCtD
Thalidomide—Discomfort—Capecitabine—esophageal cancer	0.000146	0.000966	CcSEcCtD
Thalidomide—Urethral disorder—Methotrexate—esophageal cancer	0.000146	0.000963	CcSEcCtD
Thalidomide—Dry mouth—Capecitabine—esophageal cancer	0.000145	0.000957	CcSEcCtD
Thalidomide—Visual impairment—Methotrexate—esophageal cancer	0.000143	0.000947	CcSEcCtD
Thalidomide—Confusional state—Capecitabine—esophageal cancer	0.000143	0.000945	CcSEcCtD
Thalidomide—Oedema—Capecitabine—esophageal cancer	0.000142	0.000938	CcSEcCtD
Thalidomide—Hypersensitivity—Cisplatin—esophageal cancer	0.000142	0.000937	CcSEcCtD
Thalidomide—Infection—Capecitabine—esophageal cancer	0.000141	0.000931	CcSEcCtD
Thalidomide—Erythema multiforme—Methotrexate—esophageal cancer	0.00014	0.000929	CcSEcCtD
Thalidomide—Shock—Capecitabine—esophageal cancer	0.000139	0.000922	CcSEcCtD
Thalidomide—Nervous system disorder—Capecitabine—esophageal cancer	0.000139	0.000919	CcSEcCtD
Thalidomide—Eye disorder—Methotrexate—esophageal cancer	0.000139	0.000918	CcSEcCtD
Thalidomide—Thrombocytopenia—Capecitabine—esophageal cancer	0.000139	0.000918	CcSEcCtD
Thalidomide—Tinnitus—Methotrexate—esophageal cancer	0.000138	0.000916	CcSEcCtD
Thalidomide—Tachycardia—Capecitabine—esophageal cancer	0.000138	0.000915	CcSEcCtD
Thalidomide—Asthenia—Cisplatin—esophageal cancer	0.000138	0.000913	CcSEcCtD
Thalidomide—Cardiac disorder—Methotrexate—esophageal cancer	0.000138	0.000912	CcSEcCtD
Thalidomide—Skin disorder—Capecitabine—esophageal cancer	0.000138	0.000911	CcSEcCtD
Thalidomide—Hyperhidrosis—Capecitabine—esophageal cancer	0.000137	0.000906	CcSEcCtD
Thalidomide—Anorexia—Capecitabine—esophageal cancer	0.000135	0.000894	CcSEcCtD
Thalidomide—Angiopathy—Methotrexate—esophageal cancer	0.000135	0.000891	CcSEcCtD
Thalidomide—Immune system disorder—Methotrexate—esophageal cancer	0.000134	0.000887	CcSEcCtD
Thalidomide—Mediastinal disorder—Methotrexate—esophageal cancer	0.000134	0.000885	CcSEcCtD
Thalidomide—Chills—Methotrexate—esophageal cancer	0.000133	0.000881	CcSEcCtD
Thalidomide—Hypotension—Capecitabine—esophageal cancer	0.000132	0.000876	CcSEcCtD
Thalidomide—Diarrhoea—Cisplatin—esophageal cancer	0.000132	0.00087	CcSEcCtD
Thalidomide—Alopecia—Methotrexate—esophageal cancer	0.000131	0.000868	CcSEcCtD
Thalidomide—Mental disorder—Methotrexate—esophageal cancer	0.00013	0.000861	CcSEcCtD
Thalidomide—Malnutrition—Methotrexate—esophageal cancer	0.000129	0.000855	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000129	0.000854	CcSEcCtD
Thalidomide—Insomnia—Capecitabine—esophageal cancer	0.000128	0.000848	CcSEcCtD
Thalidomide—Paraesthesia—Capecitabine—esophageal cancer	0.000127	0.000842	CcSEcCtD
Thalidomide—Dysgeusia—Methotrexate—esophageal cancer	0.000127	0.000837	CcSEcCtD
Thalidomide—Dyspnoea—Capecitabine—esophageal cancer	0.000126	0.000836	CcSEcCtD
Thalidomide—Back pain—Methotrexate—esophageal cancer	0.000125	0.000827	CcSEcCtD
Thalidomide—Dyspepsia—Capecitabine—esophageal cancer	0.000125	0.000825	CcSEcCtD
Thalidomide—Decreased appetite—Capecitabine—esophageal cancer	0.000123	0.000815	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000122	0.000809	CcSEcCtD
Thalidomide—Vomiting—Cisplatin—esophageal cancer	0.000122	0.000809	CcSEcCtD
Thalidomide—Fatigue—Capecitabine—esophageal cancer	0.000122	0.000808	CcSEcCtD
Thalidomide—Vision blurred—Methotrexate—esophageal cancer	0.000122	0.000806	CcSEcCtD
Thalidomide—Rash—Cisplatin—esophageal cancer	0.000121	0.000802	CcSEcCtD
Thalidomide—Pain—Capecitabine—esophageal cancer	0.000121	0.000802	CcSEcCtD
Thalidomide—Constipation—Capecitabine—esophageal cancer	0.000121	0.000802	CcSEcCtD
Thalidomide—Dermatitis—Cisplatin—esophageal cancer	0.000121	0.000801	CcSEcCtD
Thalidomide—Ill-defined disorder—Methotrexate—esophageal cancer	0.00012	0.000793	CcSEcCtD
Thalidomide—Anaemia—Methotrexate—esophageal cancer	0.000119	0.00079	CcSEcCtD
Thalidomide—Feeling abnormal—Capecitabine—esophageal cancer	0.000117	0.000773	CcSEcCtD
Thalidomide—Malaise—Methotrexate—esophageal cancer	0.000117	0.000771	CcSEcCtD
Thalidomide—Vertigo—Methotrexate—esophageal cancer	0.000116	0.000768	CcSEcCtD
Thalidomide—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000116	0.000767	CcSEcCtD
Thalidomide—Leukopenia—Methotrexate—esophageal cancer	0.000116	0.000766	CcSEcCtD
Thalidomide—Nausea—Cisplatin—esophageal cancer	0.000114	0.000756	CcSEcCtD
Thalidomide—Cough—Methotrexate—esophageal cancer	0.000113	0.000746	CcSEcCtD
Thalidomide—Urticaria—Capecitabine—esophageal cancer	0.000113	0.000745	CcSEcCtD
Thalidomide—Abdominal pain—Capecitabine—esophageal cancer	0.000112	0.000741	CcSEcCtD
Thalidomide—Body temperature increased—Capecitabine—esophageal cancer	0.000112	0.000741	CcSEcCtD
Thalidomide—Convulsion—Methotrexate—esophageal cancer	0.000112	0.000741	CcSEcCtD
Thalidomide—Myalgia—Methotrexate—esophageal cancer	0.00011	0.000728	CcSEcCtD
Thalidomide—Chest pain—Methotrexate—esophageal cancer	0.00011	0.000728	CcSEcCtD
Thalidomide—Arthralgia—Methotrexate—esophageal cancer	0.00011	0.000728	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000109	0.000723	CcSEcCtD
Thalidomide—Discomfort—Methotrexate—esophageal cancer	0.000109	0.000719	CcSEcCtD
Thalidomide—Confusional state—Methotrexate—esophageal cancer	0.000106	0.000704	CcSEcCtD
Thalidomide—Infection—Methotrexate—esophageal cancer	0.000105	0.000693	CcSEcCtD
Thalidomide—Hypersensitivity—Capecitabine—esophageal cancer	0.000104	0.000691	CcSEcCtD
Thalidomide—Nervous system disorder—Methotrexate—esophageal cancer	0.000103	0.000684	CcSEcCtD
Thalidomide—Thrombocytopenia—Methotrexate—esophageal cancer	0.000103	0.000683	CcSEcCtD
Thalidomide—Skin disorder—Methotrexate—esophageal cancer	0.000102	0.000678	CcSEcCtD
Thalidomide—Hyperhidrosis—Methotrexate—esophageal cancer	0.000102	0.000675	CcSEcCtD
Thalidomide—Asthenia—Capecitabine—esophageal cancer	0.000102	0.000673	CcSEcCtD
Thalidomide—Anorexia—Methotrexate—esophageal cancer	0.000101	0.000665	CcSEcCtD
Thalidomide—Pruritus—Capecitabine—esophageal cancer	0.0001	0.000663	CcSEcCtD
Thalidomide—Hypotension—Methotrexate—esophageal cancer	9.86e-05	0.000652	CcSEcCtD
Thalidomide—Diarrhoea—Capecitabine—esophageal cancer	9.7e-05	0.000642	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Methotrexate—esophageal cancer	9.61e-05	0.000636	CcSEcCtD
Thalidomide—Insomnia—Methotrexate—esophageal cancer	9.54e-05	0.000631	CcSEcCtD
Thalidomide—Paraesthesia—Methotrexate—esophageal cancer	9.47e-05	0.000627	CcSEcCtD
Thalidomide—Dyspnoea—Methotrexate—esophageal cancer	9.41e-05	0.000622	CcSEcCtD
Thalidomide—Somnolence—Methotrexate—esophageal cancer	9.38e-05	0.00062	CcSEcCtD
Thalidomide—Dizziness—Capecitabine—esophageal cancer	9.37e-05	0.00062	CcSEcCtD
Thalidomide—Dyspepsia—Methotrexate—esophageal cancer	9.29e-05	0.000614	CcSEcCtD
Thalidomide—Decreased appetite—Methotrexate—esophageal cancer	9.17e-05	0.000607	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Methotrexate—esophageal cancer	9.11e-05	0.000603	CcSEcCtD
Thalidomide—Fatigue—Methotrexate—esophageal cancer	9.1e-05	0.000602	CcSEcCtD
Thalidomide—Pain—Methotrexate—esophageal cancer	9.02e-05	0.000597	CcSEcCtD
Thalidomide—Vomiting—Capecitabine—esophageal cancer	9.01e-05	0.000596	CcSEcCtD
Thalidomide—Rash—Capecitabine—esophageal cancer	8.94e-05	0.000591	CcSEcCtD
Thalidomide—Dermatitis—Capecitabine—esophageal cancer	8.93e-05	0.000591	CcSEcCtD
Thalidomide—Headache—Capecitabine—esophageal cancer	8.88e-05	0.000587	CcSEcCtD
Thalidomide—Feeling abnormal—Methotrexate—esophageal cancer	8.69e-05	0.000575	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methotrexate—esophageal cancer	8.63e-05	0.000571	CcSEcCtD
Thalidomide—Nausea—Capecitabine—esophageal cancer	8.42e-05	0.000557	CcSEcCtD
Thalidomide—Urticaria—Methotrexate—esophageal cancer	8.38e-05	0.000554	CcSEcCtD
Thalidomide—Abdominal pain—Methotrexate—esophageal cancer	8.34e-05	0.000552	CcSEcCtD
Thalidomide—Body temperature increased—Methotrexate—esophageal cancer	8.34e-05	0.000552	CcSEcCtD
Thalidomide—Hypersensitivity—Methotrexate—esophageal cancer	7.77e-05	0.000514	CcSEcCtD
Thalidomide—Asthenia—Methotrexate—esophageal cancer	7.57e-05	0.000501	CcSEcCtD
Thalidomide—Pruritus—Methotrexate—esophageal cancer	7.46e-05	0.000494	CcSEcCtD
Thalidomide—Diarrhoea—Methotrexate—esophageal cancer	7.22e-05	0.000478	CcSEcCtD
Thalidomide—Dizziness—Methotrexate—esophageal cancer	6.98e-05	0.000462	CcSEcCtD
Thalidomide—Vomiting—Methotrexate—esophageal cancer	6.71e-05	0.000444	CcSEcCtD
Thalidomide—Rash—Methotrexate—esophageal cancer	6.65e-05	0.00044	CcSEcCtD
Thalidomide—Dermatitis—Methotrexate—esophageal cancer	6.65e-05	0.00044	CcSEcCtD
Thalidomide—Headache—Methotrexate—esophageal cancer	6.61e-05	0.000437	CcSEcCtD
Thalidomide—Nausea—Methotrexate—esophageal cancer	6.27e-05	0.000415	CcSEcCtD
Thalidomide—FGFR2—Adaptive Immune System—EGFR—esophageal cancer	1.33e-05	7.25e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ADH1B—esophageal cancer	1.32e-05	7.19e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CALR—esophageal cancer	1.29e-05	7.02e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GAPDH—esophageal cancer	1.28e-05	7.01e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GNG7—esophageal cancer	1.28e-05	7.01e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CREBBP—esophageal cancer	1.28e-05	7e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GNG7—esophageal cancer	1.28e-05	6.99e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ALDH2—esophageal cancer	1.28e-05	6.98e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CRABP1—esophageal cancer	1.27e-05	6.95e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—PIK3CA—esophageal cancer	1.27e-05	6.91e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—BCL2—esophageal cancer	1.26e-05	6.88e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CA2—esophageal cancer	1.26e-05	6.87e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TYMP—esophageal cancer	1.26e-05	6.87e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EGFR—esophageal cancer	1.26e-05	6.87e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FBXW7—esophageal cancer	1.24e-05	6.79e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.24e-05	6.74e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	1.23e-05	6.72e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—ERBB2—esophageal cancer	1.23e-05	6.69e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP26A1—esophageal cancer	1.23e-05	6.69e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP1B1—esophageal cancer	1.22e-05	6.66e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—GSTT1—esophageal cancer	1.22e-05	6.64e-05	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—PIK3CA—esophageal cancer	1.22e-05	6.63e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GNG7—esophageal cancer	1.21e-05	6.61e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ALDH2—esophageal cancer	1.2e-05	6.57e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP2A6—esophageal cancer	1.2e-05	6.56e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ADH1B—esophageal cancer	1.2e-05	6.56e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—PIK3CA—esophageal cancer	1.2e-05	6.55e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ALDH2—esophageal cancer	1.2e-05	6.55e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.2e-05	6.53e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—BCL2—esophageal cancer	1.2e-05	6.53e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALOX15—esophageal cancer	1.19e-05	6.51e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADH7—esophageal cancer	1.17e-05	6.39e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLCE1—esophageal cancer	1.17e-05	6.39e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—ERBB2—esophageal cancer	1.16e-05	6.35e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HIF1A—esophageal cancer	1.16e-05	6.32e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	1.16e-05	6.32e-05	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—PIK3CA—esophageal cancer	1.15e-05	6.29e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TYMP—esophageal cancer	1.15e-05	6.27e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NOS3—esophageal cancer	1.15e-05	6.26e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CYP19A1—esophageal cancer	1.15e-05	6.26e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—GSTT1—esophageal cancer	1.14e-05	6.25e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—GSTT1—esophageal cancer	1.14e-05	6.23e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ENO1—esophageal cancer	1.14e-05	6.22e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PTGS1—esophageal cancer	1.14e-05	6.22e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTO1—esophageal cancer	1.14e-05	6.21e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TPI1—esophageal cancer	1.14e-05	6.21e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ALDH2—esophageal cancer	1.13e-05	6.19e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP2A6—esophageal cancer	1.13e-05	6.17e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP2A6—esophageal cancer	1.13e-05	6.16e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PSME2—esophageal cancer	1.12e-05	6.13e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PSME1—esophageal cancer	1.12e-05	6.13e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP26A1—esophageal cancer	1.12e-05	6.1e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KDR—esophageal cancer	1.11e-05	6.05e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HIF1A—esophageal cancer	1.1e-05	6e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALDOB—esophageal cancer	1.09e-05	5.96e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALOX15—esophageal cancer	1.09e-05	5.94e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—GSTT1—esophageal cancer	1.08e-05	5.89e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—ERBB2—esophageal cancer	1.07e-05	5.86e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ENO1—esophageal cancer	1.07e-05	5.85e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS1—esophageal cancer	1.07e-05	5.85e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ENO1—esophageal cancer	1.07e-05	5.84e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS1—esophageal cancer	1.07e-05	5.84e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP2A6—esophageal cancer	1.07e-05	5.82e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.06e-05	5.8e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PSME1—esophageal cancer	1.06e-05	5.77e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PSME2—esophageal cancer	1.06e-05	5.77e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PSME1—esophageal cancer	1.05e-05	5.76e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PSME2—esophageal cancer	1.05e-05	5.76e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KDR—esophageal cancer	1.05e-05	5.74e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GAPDH—esophageal cancer	1.05e-05	5.74e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—esophageal cancer	1.05e-05	5.73e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CDKN1A—esophageal cancer	1.05e-05	5.72e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—HMOX1—esophageal cancer	1.05e-05	5.71e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOTCH1—esophageal cancer	1.04e-05	5.69e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CRABP1—esophageal cancer	1.04e-05	5.68e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTO1—esophageal cancer	1.04e-05	5.67e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TPI1—esophageal cancer	1.04e-05	5.67e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.03e-05	5.61e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ADH1B—esophageal cancer	1.03e-05	5.6e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS1—esophageal cancer	1.01e-05	5.52e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ENO1—esophageal cancer	1.01e-05	5.52e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFBR2—esophageal cancer	1.01e-05	5.49e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ABCB1—esophageal cancer	1.01e-05	5.48e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EP300—esophageal cancer	9.97e-06	5.44e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PSME2—esophageal cancer	9.97e-06	5.44e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PSME1—esophageal cancer	9.97e-06	5.44e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALDOB—esophageal cancer	9.96e-06	5.43e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CDKN1A—esophageal cancer	9.94e-06	5.42e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GNG7—esophageal cancer	9.91e-06	5.41e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOTCH1—esophageal cancer	9.9e-06	5.4e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TYMP—esophageal cancer	9.81e-06	5.35e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP1B1—esophageal cancer	9.69e-06	5.29e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GAPDH—esophageal cancer	9.58e-06	5.23e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP26A1—esophageal cancer	9.55e-06	5.21e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SMAD4—esophageal cancer	9.53e-06	5.2e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CRABP1—esophageal cancer	9.5e-06	5.18e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CREBBP—esophageal cancer	9.46e-06	5.16e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EP300—esophageal cancer	9.46e-06	5.16e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALOX15—esophageal cancer	9.3e-06	5.08e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ALDH2—esophageal cancer	9.29e-06	5.07e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CDKN1A—esophageal cancer	9.18e-06	5.01e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP1B1—esophageal cancer	9.12e-06	4.98e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP19A1—esophageal cancer	9.11e-06	4.97e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP1B1—esophageal cancer	9.1e-06	4.97e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GNG7—esophageal cancer	9.04e-06	4.93e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CREBBP—esophageal cancer	8.98e-06	4.9e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTO1—esophageal cancer	8.88e-06	4.84e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TPI1—esophageal cancer	8.88e-06	4.84e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GSTT1—esophageal cancer	8.83e-06	4.82e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EP300—esophageal cancer	8.73e-06	4.76e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP2A6—esophageal cancer	8.73e-06	4.76e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.7e-06	4.75e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	8.7e-06	4.75e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP1B1—esophageal cancer	8.6e-06	4.69e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP19A1—esophageal cancer	8.58e-06	4.68e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP19A1—esophageal cancer	8.56e-06	4.67e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALDOB—esophageal cancer	8.51e-06	4.64e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EGFR—esophageal cancer	8.5e-06	4.64e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOS3—esophageal cancer	8.47e-06	4.62e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ALDH2—esophageal cancer	8.47e-06	4.62e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—HMOX1—esophageal cancer	8.31e-06	4.54e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ENO1—esophageal cancer	8.28e-06	4.52e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS1—esophageal cancer	8.28e-06	4.52e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GAPDH—esophageal cancer	8.19e-06	4.47e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	8.16e-06	4.45e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PSME1—esophageal cancer	8.16e-06	4.45e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PSME2—esophageal cancer	8.16e-06	4.45e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CRABP1—esophageal cancer	8.12e-06	4.43e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP19A1—esophageal cancer	8.09e-06	4.41e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EGFR—esophageal cancer	8.06e-06	4.4e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GSTT1—esophageal cancer	8.05e-06	4.39e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOS3—esophageal cancer	8.04e-06	4.39e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ABCB1—esophageal cancer	7.98e-06	4.35e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP2A6—esophageal cancer	7.96e-06	4.34e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	7.93e-06	4.33e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ERBB2—esophageal cancer	7.93e-06	4.32e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—HMOX1—esophageal cancer	7.83e-06	4.27e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—HMOX1—esophageal cancer	7.81e-06	4.26e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HIF1A—esophageal cancer	7.8e-06	4.25e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GNG7—esophageal cancer	7.72e-06	4.21e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MYC—esophageal cancer	7.61e-06	4.15e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.6e-06	4.15e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS1—esophageal cancer	7.55e-06	4.12e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ENO1—esophageal cancer	7.55e-06	4.12e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ERBB2—esophageal cancer	7.52e-06	4.1e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ABCB1—esophageal cancer	7.51e-06	4.1e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ABCB1—esophageal cancer	7.5e-06	4.09e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EGFR—esophageal cancer	7.44e-06	4.06e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PSME2—esophageal cancer	7.44e-06	4.06e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PSME1—esophageal cancer	7.44e-06	4.06e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—HMOX1—esophageal cancer	7.38e-06	4.03e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PIK3CA—esophageal cancer	7.37e-06	4.02e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	7.24e-06	3.95e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ALDH2—esophageal cancer	7.23e-06	3.95e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	7.12e-06	3.89e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS2—esophageal cancer	7.09e-06	3.87e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ABCB1—esophageal cancer	7.08e-06	3.86e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP1B1—esophageal cancer	7.04e-06	3.84e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOTCH1—esophageal cancer	7.02e-06	3.83e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCND1—esophageal cancer	7e-06	3.82e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PIK3CA—esophageal cancer	7e-06	3.82e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GSTT1—esophageal cancer	6.88e-06	3.75e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2A6—esophageal cancer	6.8e-06	3.71e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	6.78e-06	3.7e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1A—esophageal cancer	6.77e-06	3.7e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CREBBP—esophageal cancer	6.72e-06	3.67e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCND1—esophageal cancer	6.64e-06	3.62e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP19A1—esophageal cancer	6.62e-06	3.61e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	6.49e-06	3.54e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PIK3CA—esophageal cancer	6.46e-06	3.52e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ENO1—esophageal cancer	6.45e-06	3.52e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS1—esophageal cancer	6.45e-06	3.52e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EP300—esophageal cancer	6.45e-06	3.52e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1A—esophageal cancer	6.43e-06	3.51e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP1B1—esophageal cancer	6.42e-06	3.5e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CREBBP—esophageal cancer	6.37e-06	3.47e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PSME2—esophageal cancer	6.35e-06	3.47e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PSME1—esophageal cancer	6.35e-06	3.47e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EP300—esophageal cancer	6.12e-06	3.34e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HMOX1—esophageal cancer	6.04e-06	3.29e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP19A1—esophageal cancer	6.03e-06	3.29e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	6.03e-06	3.29e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NOS3—esophageal cancer	6.01e-06	3.28e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.92e-06	3.23e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCB1—esophageal cancer	5.79e-06	3.16e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS3—esophageal cancer	5.7e-06	3.11e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—esophageal cancer	5.62e-06	3.06e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5.55e-06	3.03e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HMOX1—esophageal cancer	5.51e-06	3e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—esophageal cancer	5.5e-06	3e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—esophageal cancer	5.49e-06	3e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP1B1—esophageal cancer	5.48e-06	2.99e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.4e-06	2.95e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	5.35e-06	2.92e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CREBBP—esophageal cancer	5.33e-06	2.91e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ERBB2—esophageal cancer	5.33e-06	2.91e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—esophageal cancer	5.33e-06	2.91e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCB1—esophageal cancer	5.28e-06	2.88e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—esophageal cancer	5.21e-06	2.84e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP19A1—esophageal cancer	5.16e-06	2.81e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CREBBP—esophageal cancer	5.02e-06	2.74e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CREBBP—esophageal cancer	5.01e-06	2.73e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NOS3—esophageal cancer	4.77e-06	2.61e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CA—esophageal cancer	4.77e-06	2.6e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CREBBP—esophageal cancer	4.73e-06	2.58e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HMOX1—esophageal cancer	4.7e-06	2.57e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.61e-06	2.52e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—esophageal cancer	4.61e-06	2.52e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—EP300—esophageal cancer	4.58e-06	2.5e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1A—esophageal cancer	4.56e-06	2.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CA—esophageal cancer	4.52e-06	2.47e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCB1—esophageal cancer	4.52e-06	2.46e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NOS3—esophageal cancer	4.49e-06	2.45e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NOS3—esophageal cancer	4.49e-06	2.45e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.38e-06	2.39e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—esophageal cancer	4.38e-06	2.39e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EP300—esophageal cancer	4.34e-06	2.37e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NOS3—esophageal cancer	4.24e-06	2.31e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—esophageal cancer	4.11e-06	2.24e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—esophageal cancer	4.1e-06	2.24e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.99e-06	2.18e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—esophageal cancer	3.88e-06	2.11e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CREBBP—esophageal cancer	3.87e-06	2.11e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—esophageal cancer	3.78e-06	2.06e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—esophageal cancer	3.7e-06	2.02e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—EP300—esophageal cancer	3.63e-06	1.98e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CREBBP—esophageal cancer	3.53e-06	1.93e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NOS3—esophageal cancer	3.47e-06	1.89e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—EP300—esophageal cancer	3.42e-06	1.87e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.41e-06	1.86e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—EP300—esophageal cancer	3.41e-06	1.86e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CA—esophageal cancer	3.38e-06	1.85e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—EP300—esophageal cancer	3.22e-06	1.76e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CA—esophageal cancer	3.21e-06	1.75e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—esophageal cancer	3.17e-06	1.73e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NOS3—esophageal cancer	3.16e-06	1.73e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CREBBP—esophageal cancer	3.02e-06	1.65e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—esophageal cancer	2.89e-06	1.58e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NOS3—esophageal cancer	2.7e-06	1.47e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CA—esophageal cancer	2.69e-06	1.47e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—EP300—esophageal cancer	2.64e-06	1.44e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CA—esophageal cancer	2.53e-06	1.38e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CA—esophageal cancer	2.52e-06	1.38e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—esophageal cancer	2.47e-06	1.35e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—EP300—esophageal cancer	2.41e-06	1.31e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CA—esophageal cancer	2.38e-06	1.3e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—EP300—esophageal cancer	2.06e-06	1.12e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CA—esophageal cancer	1.95e-06	1.06e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.78e-06	9.71e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.52e-06	8.3e-06	CbGpPWpGaD
